School of Biotechnology and Health Sciences, Wuyi University, Jiangmen city, 529020, China.
International Healthcare Innovation Institute (Jiangmen), Jiangmen city, Guangdong Province 529020, China.
Int J Med Sci. 2020 Jul 9;17(12):1795-1802. doi: 10.7150/ijms.47546. eCollection 2020.
Pancreatic adenocarcinoma is a highly malignant tumor. Synergistic combinations of anticancer agents for the effective treatment of pancreatic cancer patients are urgently needed. Here, we investigated the combined effect of celecoxib (CEL) and salirasib (SAL) on pancreatic cancer cells. Cell viability and apoptosis were measured by the trypan blue assay, three-dimensional cultures, propidium iodide staining, and caspase-3 assay. NF-κB activation and the protein levels of Akt, pAkt, and Bcl-2 were determined by the luciferase reporter assay and western blot. Co-treatment with CEL and SAL had stronger effects on decreasing cell viability and inducing apoptosis in Panc-1 cells as compared with each agent individually. This combination strongly inhibited NF-κB activity and reduced pAkt and Bcl-2 levels in Panc-1 cells. SAL in combination with CEL may represent a new approach for effective inhibition of pancreatic cancer.
胰腺导管腺癌是一种高度恶性肿瘤。迫切需要联合抗癌药物来有效治疗胰腺癌患者。在这里，我们研究了塞来昔布（CEL）和沙利度胺（SAL）联合应用对胰腺癌细胞的影响。通过台盼蓝法、三维培养、碘化丙啶染色和 caspase-3 测定来检测细胞活力和细胞凋亡。通过荧光素酶报告基因检测和 Western blot 来测定 NF-κB 激活和 Akt、pAkt 和 Bcl-2 的蛋白水平。与每种药物单独处理相比，CEL 和 SAL 的联合处理对 Panc-1 细胞的活力降低和凋亡诱导作用更强。这种联合治疗强烈抑制了 NF-κB 的活性，并降低了 Panc-1 细胞中 pAkt 和 Bcl-2 的水平。SAL 联合 CEL 可能代表了一种有效抑制胰腺癌的新方法。
